GlobalData on MSN9d
FDA clears Qiagen’s QIAstat-Dx Gastrointestinal Panel 2 Mini B
The latest authorised panel targets bacterial infections, including Campylobacter, Shigella, Yersinia enterocolitica, and ...
Zacks Investment Research on MSN9d
QGEN Stock Up on FDA Nod for Second QIAstat-Dx Gastrointestinal Panel
QIAGEN N.V. QGEN has secured FDA clearance for its QIAstat-Dx Gastrointestinal Panel 2 Mini B for clinical use, bolstering its syndromic testing portfolio in the United States. This marks the ...